Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5413923

Title:Homologous recombination for universal donor cells and chimeric mammalian hosts
Inventors:Kucherlapati, Raju; Darien, CT, USA
Koller, Beverly H.; Carrboro, NC, USA
Smithies, Oliver; Chapel Hill, NC, USA
Summary:This invention describes a method by which homologous recombination is employed to inactivate genes associated with MHC antigens. Described herein are novel genetically engineered cells having lesions at the ?2 -microglobulin loci which results in cells lacking Class I MHC antigens and which may be used as universal donor cells. Further disclosed are methods by which embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts which in turn may be used as a source of universal donor organs and as models for drug and transplantation therapies.
Abstract:Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the .beta..sub.2 -microglobulin gene is inactivated for reducing or eliminating Class I MHC antigens. The resulting cells may be used as universal donors. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5413923
Application Number:US1992000990879
Date Filed:11/12/1992
Date Published:09/05/1995
Assignee:Cell Genesys, Inc., Foster City, CA, USA Univ. of North Carolina at Chapel Hill, Chapel Hill, NC, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021